Showing all 6 results

  • Clindipine Tablets

    Free

    Product Composition & Strength

    We supply this product as a Precision-Blended, Light-Shielded Cardiovascular Tablet, packed exclusively in highly secure, opaque Alu-Alu blister strips to ensure the absolute chemical stability of the highly photosensitive active ingredient.

    Active IngredientStrengthPrimary Clinical Function
    Cilnidipine USP/Ph.Eur.5 mgThe Geriatric & Titration Anchor: The definitive starting dose utilized for elderly patients or those with mild essential hypertension to prevent sudden hypotensive episodes.
    Cilnidipine USP/Ph.Eur.10 mgThe Global Maintenance Standard: The standardized daily therapeutic payload utilized for the vast majority of adult patients requiring chronic 24-hour blood pressure control.
    Cilnidipine USP/Ph.Eur.20 mgThe Severe Refractory Macrodose: Utilized strictly for severe, uncontrolled hypertension where the 10mg dose has failed to achieve target blood pressure metrics.
    ExcipientsMicrocrystalline Cellulose / Lactose Monohydrate / Croscarmellose Sodium / Hypromellose / Magnesium Stearate / Opaque Polymeric Film (Titanium Dioxide base)Diluent / Densifier / Superdisintegrant / Binder / Lubricant / Protective Light Shield (Engineered specifically utilizing a dense, titanium dioxide-heavy film coat. Cilnidipine is intensely sensitive to UV and visible light; this opaque coating guarantees 100% of the active molecule survives to reach the patient’s systemic circulation)

    *Pack Sizes: 10×10 Opaque Alu-Alu Blisters (Optimized specifically for strict 30-day chronic cardiology dispensing regimens).

  • Metoprolol & Amlodipin Tablets

    Free

    Product Composition & Strength

    We supply this product as a Precision-Engineered, API-Segregated Bilayer Tablet, packed exclusively in highly secure, moisture-resistant Alu-Alu or high-density PVC/PVDC blister strips to ensure the absolute chemical stability of the combined molecules.

    Active IngredientStrengthPrimary Clinical Function
    Metoprolol (as Tartrate/Succinate ER) Ph.Eur./USP25 mg / 50 mgCardioselective Base: Reduces heart rate, cardiac workload, and neutralizes CCB-induced reflex tachycardia.
    Amlodipine (as Besylate) Ph.Eur./USP5 mgCalcium Channel Blocker (CCB): Forces profound peripheral arterial vasodilation, dropping severe blood pressure and relieving coronary spasms.
    ExcipientsMicrocrystalline Cellulose / Dibasic Calcium Phosphate / Crospovidone / Magnesium Stearate / Premium Opadry Film / Iron Oxide ColorsDiluent / Stabilizing Buffer / Superdisintegrant / Lubricant (Engineered specifically using bilayer press technology to physically separate the slightly acidic Metoprolol salt from the basic Amlodipine, preventing destructive chemical cross-talk)

    *Pack Sizes: 10×10 Blisters (Optimized specifically for strict 30-day chronic cardiology dispensing regimens).

  • Nifedipine Tablet

    Free

    Product Composition & Structural Formats

    We manufacture Nifedipine across the complete clinical dosage spectrum, utilizing distinct release matrices calibrated for immediate stabilization or sustained, once-daily therapeutic coverage.

    Active IngredientAvailable StrengthsFormulation Matrix Delivery SystemPrimary Clinical Focus
    Nifedipine IP/BP/USP10 mgImmediate-Release / Rapid-Onset Film TabletAcute Titration / Tocolysis: For severe acute hypertension or suppression of premature labor contractions.
    Nifedipine IP/BP/USP20 mgSustained-Release (SR) Retard MatrixTwice-Daily Maintenance: Intermediate control for stable chronic hypertension.
    Nifedipine IP/BP/USP30 mgOnce-Daily Extended-Release (XR / XL) MatrixFirst-Line Chronic Care: Continuous 24-hour plasma stabilization for mild-to-moderate hypertension.
    Nifedipine IP/BP/USP60 mgOnce-Daily Extended-Release (XR / XL) MatrixHigh-Potency Control: For refractory essential hypertension and severe chronic stable angina pectoris.
  • Nifedipine Tablet

    Free

    Product Composition & Structural Formats

    We supply Nifedipine in exact, internationally standardized strengths, optimized for immediate-release emergency titration or controlled-release daily maintenance.

    Active IngredientAvailable StrengthsFormulation MechanismPrimary Clinical Target
    Nifedipine IP / BP / USP10 mgImmediate or Modified ReleaseAcute Titration / Tocolysis: For rapid blood pressure adjustment or suppression of premature labor.
    Nifedipine IP / BP / USP20 mgSustained / Retard MatrixDaily Maintenance: Continuous 12-to-24-hour plasma concentration for chronic hypertension and angina.
  • Ramipril and Amlodipine Tablets

    Free

    Product Composition & Strength

    We supply this product as a Precision-Blended Capsule or Film-Coated Tablet, packed exclusively in highly secure, moisture-resistant Alu-Alu blister strips to ensure the absolute chemical stability of the highly degradable Ramipril molecule.

    Active IngredientStrengthPrimary Clinical Function
    Ramipril Ph.Eur./USP5 mg / 10 mgACE inhibition for vasodilation, neurohormonal blockade, and venous pressure equalization.
    Amlodipine (as Besilate) Ph.Eur./USP5 mg / 10 mgGlobal Clinical Standard: Sustained CCB for profound, 24-hour arterial vasodilation.
    ExcipientsMicrocrystalline Cellulose / Crospovidone / Sodium Stearyl Fumarate / Hypromellose / Iron Oxide RedDiluent / Superdisintegrant / Alkaline Stabilizing Lubricant (Engineered to protect Ramipril from acidic degradation and moisture)

    *Pack Sizes: 10×10 Alu-Alu Blisters or 3×10 Unit-Dose Blisters (Optimized specifically for strict, high-compliance 30-day chronic cardiology dispensing regimens).

  • Verapamil Tablets

    Free

    Product Composition & Strength

    We supply this product as Sugar Coated Tablets (Immediate Release) or Film Coated Tablets (Sustained Release – SR).

    Active IngredientStrength (Standard)Therapeutic Role
    Verapamil HCl USP/BP40 mg / 80 mgImmediate Release (Arrhythmia)
    Verapamil HCl USP/BP120 mg (SR)Sustained Release (Hypertension)
    Verapamil HCl USP/BP240 mg (SR)High Dose / Once Daily
    ExcipientsQ.S.Sodium Alginate / HPMCSR Matrix Former